Pharmaceuticals
Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation (exon20ins)
* Treatment with ZEGFROVY® resulted in statistically significant and clinically meaningful improvement in progression free survival (PFS) over platinum-containing chemo doublet * WU-KONG 28 is the first and only phase 3 study to demonstrate meaningful benefits with an oral, once daily, chemo-...
2026-03-21 19:26
9129
Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development
WILMINGTON, Del., March 20, 2026 /PRNewswire/ -- Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, today announced that it has raised$787 million in financing rounds. The investment included participation by a group of leading global investors, including Dimen...
2026-03-20 19:30
7125
Bambusa Therapeutics Appoints Todd James Chief Financial Officer
- Mr. James brings more than 20 years of biopharmaceutical leadership experience, with deep expertise in capital markets, investor relations, and corporate strategy, serving in senior executive roles at Acceleron Pharma prior to its$11.5 billion acquisition by Merck and at Viridian Therapeutics -...
2026-03-19 20:30
8834
Ractigen Therapeutics Announces China NMPA IND Approval for Phase II Clinical Trial of saRNA Therapy RAG-01 in Non-Muscle Invasive Bladder Cancer
NANTONG, China, March 19, 2026 /PRNewswire/ -- Ractigen Therapeutics, a pioneering clinical-stage biotechnology company developing innovative small activating RNA (saRNA) therapeutics, today announced thatChina's National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has...
2026-03-19 20:10
7316
SK bioscience Secures Funding to Advance RSV Preventive Antibody Development with RIGHT Foundation Support
* Largest-ever grant from RIGHT Foundation to accelerate Phase 1b clinical trial of RSV preventive antibody * Technology licensed from Gates MRI; early studies confirm suppression of RSV infection * Targeting global markets while addressing unmet needs in developing countries INCHEON, South...
2026-03-18 20:00
8721
Breakthrough at 2026 AACR! Senhwa Biosciences' CX-5461 Enters the Field of Photodynamic Therapy, Opening a New Indication Strategy
TAIPEI and SAN DIEGO, March 17, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage company focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that its first-in-class investigational drug Pidnarule...
2026-03-18 07:00
8476
Laronix Launches Voice Restoration Study for ICU Patients at Greater Baltimore Medical Center
NEW YORK, March 16, 2026 /PRNewswire/ -- Laronix, Inc., a commercial-stage medical technology (MedTech) company and industry-leading innovator in voice restoration technologies, and the Greater Baltimore Medical Center (GBMC) announced the launch of an investigational study of Laronix MIRA Voice ...
2026-03-16 22:20
3630
Alar Announced Buprenorphine Injectable, ALA-1000, Demonstrated Long-Term Efficacy and Favorable Safety Profile in Canine Osteoarthritis Pain Management
* A study in client-owned dogs with osteoarthritis demonstrated that a single injection of ALA-1000 effectively mitigates pain and improves functional mobility, with a sustained drug release profile for at least 1 month. The study also confirmed a favorable safety profile with repeated use, par...
2026-03-16 20:00
4536
Celltrion announces U.S. availability of AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation
* AVTOZMA® (tocilizumab-anoh) is among the first wave of tocilizumab biosimilars with both intravenous (IV) and subcutaneous (SC) formulations approved and commercially available inthe United States * The launch of AVTOZMA SC further diversifies Celltrion's immunology portfolio beyond TNF-alp...
2026-03-16 20:00
6534
Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance
HONG KONG, March 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that its proprietary first-in-class trispecific antibody, AK150 (ILT2/ILT4/CSF1R), has received Investigational New Drug (IND) clearance from the National Medical Products Administration (N...
2026-03-16 10:05
7281
Vimgreen's Novel A2AR Antagonist Receives CDE IND Approval for NASH/MASH Therapy
HANGZHOU, China, March 14, 2026 /PRNewswire/ -- Vimgreen Pharmaceuticals, a leading innovator in adenosine signaling modulation, today announced the approval of its Investigational New Drug (IND) application for VG081821 in non‑alcoholic steatohepatitis (NASH), increasingly referred to as metabol...
2026-03-14 12:33
5023
BioDlink Named "Emerging CDMO of the Year" at the 2026 Asia-Pacific Biopharma Excellence Awards
* BioDlink has been named "Emerging CDMO of the Year" for its innovation in complex biologics and ADC development. * The award recognizes its proprietary technology platforms, scalable manufacturing, and a proven quality system with over 100 audits completed. SUZHOU,China, March 13, 2026 /PRN...
2026-03-13 21:00
8120
WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation
SINGAPORE, March 12, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won six prestigious awards and two individual leadership awards at the 2026 Asia-Pacific Biopharma Excelle...
2026-03-13 11:09
5363
PRISM BioLab and Receptor.AI Announce Drug Discovery Collaboration Agreement
— Advancing the Discovery of Novel Therapies and Building an Integrated Drug Discovery Platform by Combining PPI Science with AI — TOKYO, March 12, 2026 /PRNewswire/ -- PRISM BioLab Co., Ltd. ("PRISM") and Receptor.AI Inc. today announced that they have entered into a drug discovery collaboratio...
2026-03-13 08:00
3877
ImmunoForge to Conduct Strategic Partnering at Bio-Europe Spring 2026
* Conducting global licensing partnering of LMT15, a proprietary BBB Shuttle platform * Also discussing global out-licensing of Phase 2 stage new drugs PF1801 and PF1804 SEOUL, South Korea, March 12, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd. , a biopharmaceutical company developing treatments...
2026-03-12 16:58
5663
GC Biopharma Publishes a Comprehensive Review Paper Summarizing 30 Years of Accumulated Data on Its Proprietary Varicella Vaccine Strain, 'MAV/06'
* Demonstrates effectiveness comparable to the global standard Oka strain vaccine YONGIN, South Korea, March 11, 2026 /PRNewswire/ -- GC Biopharma(006280.KS), a leading provider of biopharmaceutical products inSouth Korea, announced today that a review paper comprehensively analyzing the safety...
2026-03-11 13:50
6453
The 0.05 EU/mg Breakthrough: How Sino Biological ProPure™ Is Redefining the Ultra-Low Endotoxin Standard
HOUSTON, March 10, 2026 /PRNewswire/ -- While exotoxins dominate discussions of bacterial infections, endotoxins—cell wall components released upon bacterial death—are equally dangerous. These endotoxins trigger hyperinflammatory responses that spiral into endotoxemia, in which bloodstream endoto...
2026-03-10 15:22
5156
IgHM - A New Breakthrough in Immunonutrition
HO CHI MINH CITY, Vietnam, March 9, 2026 /PRNewswire/ -- With an orientated development based on scientific nutrition, VitaDairy (Vietnam) has officially introduced its new ColosBaby Lactoferrin - a nutritional formula, which is utilized with many superior nutrients such as a super-immune complex...
2026-03-09 19:13
4412
Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 9, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, and Kelun-Biotech (6990.HK) today announced ...
2026-03-09 16:32
6760
Leads Biolabs' Opamtistomig (LBL-024) Enrolls First ESCC Patient, Exploring Dual PD-L1/4-1BB Mechanism for Superior Survival Benefits in China's High-Incidence Cancer
NANJING, China, March 9, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK)announced on March 6, 2026 that the first patient has been successfully dosed in a Phase Ⅱ clinical study evaluating Opamtistomig (LBL-024), the company's core inve...
2026-03-09 14:28
7739
Week's Top Stories
Most Reposted
/C O R R E C T I O N - Autodesk, Inc./
[Picked up by 1321 media titles]
2026-10-29 01:23
TD Brings its Global Asset Management Businesses Under One Name
[Picked up by 1167 media titles]
2026-11-02 20:00Waters Launches AI-Powered Peak Integration Expanding its Suite of Premium AI Subscription Capabilities for Empower Software
[Picked up by 1148 media titles]
2026-10-28 20:30Piramal Pharma Limited Announces Results for Q2 and H1 FY27
[Picked up by 1084 media titles]
2026-10-28 03:28Fintech OPay Raises $304 Million Ahead of NYSE Debut: NYSE Content Update
[Picked up by 1079 media titles]
2026-10-30 22:34
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
59051
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
54027
iQIYI Launches China's First AI Film Studio in Shanghai, with Inaugural Title "Cop in Trouble" in Production
2026-11-02 09:52
52116
Korean Derma Skincare Brand MDP+ Launches at Nordstrom
2026-11-03 00:30
21563
Lorikeet Dreamweaver enables businesses to give every customer an AI account manager
2026-11-04 22:00
16868